GlassScriptPhysician profile
Linda T Wang
NPI 1073794368
$7,554.52
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,416 · 2020: $1,220 · 2021: $1,072 · 2022: $1,383 · 2023: $1,397 · 2024: $66.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,404 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,404.32 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $910.47 | 2019-2024 | Mounjaro, Trulicity, Lyumjev |
| Mannkind Corporation | $714.55 | 2019-2023 | Afrezza |
| Astrazeneca Pharmaceuticals LP | $624.06 | 2019-2023 | Farxiga |
| Dexcom, INC. | $618.12 | 2019-2023 | Dexcom G6 Transmitter |
| Insulet Corporation | $543.46 | 2019-2023 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $413.21 | 2019-2023 | Tradjenta, Jardiance |
| Novo Nordisk INC | $402.30 | 2019-2022 | |
| Radius Health, INC. | $361.39 | 2019-2024 | Tymlos |
| Sanofi-Aventis U.S. LLC | $354.40 | 2019-2023 | |
| Amgen INC. | $316.47 | 2019-2023 | Evenity |
| Abbott Laboratories | $302.77 | 2020-2024 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $272.12 | 2019 | |
| Abbvie INC. | $271.46 | 2019-2022 | |
| Horizon Therapeutics Plc | $246.24 | 2019-2023 | Tepezza |
| Valeritas, INC. | $218.60 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $215.72 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $123.12 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $97.96 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $64.19 | 2019-2022 | |
| Zealand Pharma US, INC. | $58.40 | 2020-2021 | |
| Cequr Corporation | $53.33 | 2023 | Cequr Simplicity |
| Ascensia Diabetes Care US INC. | $51.82 | 2021-2023 | |
| Vistapharm, INC. | $46.79 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.76 | 2020 | |
| Bigfoot Biomedical INC | $45.93 | 2021-2022 | |
| Embecta Corp. | $30.40 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Shire North American Group INC | $29.09 | 2019 | |
| Xeris Pharmaceuticals, INC. | $23.71 | 2020 | |
| Lifescan, INC. | $22.23 | 2020 | |
| Becton, Dickinson and Company | $21.95 | 2019 | |
| Kyowa Kirin, INC. | $20.35 | 2023 | Crysvita |
| Medtronic, INC. | $17.25 | 2021 | |
| Terumo Medical Corporation | $15.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linda Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.